The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
An accomplished R&D leader and champion of the application of AI to drug discovery
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The deal includes upfront payments, milestone payments and ongoing royalties
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Subscribe To Our Newsletter & Stay Updated
